Literature DB >> 16383255

Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis.

Matthew Wetzel1, Daniel R D Premkumar, Beth Arnold, Ian F Pollack.   

Abstract

OBJECT: Trichostatin A (TSA) is a histone deacetylase inhibitor that causes growth inhibition of malignant cells. The authors' goal was to evaluate its effect on cell growth and cell cycle regulation in a large panel of glioma cell lines, as well as in human astrocytes, fibroblasts, and endothelial cells.
METHODS: Cell growth in response to TSA was evaluated using a tetrazolium colorimetric assay and a clonogenic assay. Cell cycle effects were examined using flow cytometry. A DNA fragmentation assay was used to evaluate induction of apoptosis. Histone acetylation status and the expression of p21WAF1, phosphorylated retinoblastoma protein (Rb), poly(adenosine diphosphate-ribose) polymerase (PARP), and caspase-3 were studied using Western blot analysis. In the glioma cell lines, there was significant inhibition of cell growth and detection of increased levels of acetylated histones after TSA treatment. The mechanisms underlying the growth inhibition include cell cycle arrest at the G2/M phase and apoptosis induction. The expression of p21WAF1 was activated, with a temporally related decrease in levels of phosphorylated Rb. Apoptosis was preceded by detection of cleaved PARP and activated caspase-3. The effects of TSA were less pronounced or absent in human astrocytes, fibroblasts, and endothelial cells.
CONCLUSIONS: The TSA caused inhibition of glioma cell growth by both cell cycle arrest and apoptosis. Cell cycle arrest was associated with an increase in p21WAF1 expression and a decrease in phosphorylated Rb. Apoptosis was mediated at least partly through the activation of caspase-3. Because of the differential effects in glioma cells compared with nonneoplastic cells, TSA may provide a novel strategy for achieving tumor growth inhibition and cytotoxicity. Further investigation is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16383255     DOI: 10.3171/ped.2005.103.6.0549

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  26 in total

1.  P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells.

Authors:  K Bajbouj; C Mawrin; R Hartig; J Schulze-Luehrmann; A Wilisch-Neumann; A Roessner; R Schneider-Stock
Journal:  J Neurooncol       Date:  2012-01-20       Impact factor: 4.130

2.  The Scar-in-a-Jar: studying potential antifibrotic compounds from the epigenetic to extracellular level in a single well.

Authors:  C Z C Chen; Y X Peng; Z B Wang; P V Fish; J L Kaar; R R Koepsel; A J Russell; R R Lareu; M Raghunath
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

3.  Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.

Authors:  J Drappatz; E Q Lee; S Hammond; S A Grimm; A D Norden; R Beroukhim; M Gerard; D Schiff; A S Chi; T T Batchelor; L M Doherty; A S Ciampa; D C Lafrankie; S Ruland; S M Snodgrass; J J Raizer; P Y Wen
Journal:  J Neurooncol       Date:  2011-10-08       Impact factor: 4.130

4.  Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.

Authors:  Daniel R Premkumar; Esther P Jane; Naomi R Agostino; Joseph D DiDomenico; Ian F Pollack
Journal:  Mol Carcinog       Date:  2011-11-15       Impact factor: 4.784

5.  Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine.

Authors:  Mikkel Staberg; Signe Regner Michaelsen; Rikke Darling Rasmussen; Mette Villingshøj; Hans Skovgaard Poulsen; Petra Hamerlik
Journal:  Cell Oncol (Dordr)       Date:  2016-10-20       Impact factor: 6.730

Review 6.  Epigenetics of neurological cancers.

Authors:  Shaun D Fouse; Joseph F Costello
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

7.  Mana-Hox displays anticancer activity against prostate cancer cells through tubulin depolymerization and DNA damage stress.

Authors:  Che-Jen Hsiao; Yunn-Fang Ho; John T-A Hsu; Wei-Ling Chang; Yi-Cheng Chen; Ya-Ching Shen; Ping-Chiang Lyu; Jih-Hwa Guh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-29       Impact factor: 3.000

8.  Inhibitory activities of trichostatin a in U87 glioblastoma cells and tumorsphere-derived cells.

Authors:  Felipe de Almeida Sassi; Lílian Caesar; Mariane Jaeger; Carolina Nör; Ana Lucia Abujamra; Gilberto Schwartsmann; Caroline Brunetto de Farias; Algemir Lunardi Brunetto; Patrícia Luciana da Costa Lopez; Rafael Roesler
Journal:  J Mol Neurosci       Date:  2014-01-25       Impact factor: 3.444

9.  Histone deacetylase 11 regulates oligodendrocyte-specific gene expression and cell development in OL-1 oligodendroglia cells.

Authors:  Hedi Liu; Qichen Hu; A Joseph D'ercole; Ping Ye
Journal:  Glia       Date:  2009-01-01       Impact factor: 7.452

10.  Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.

Authors:  Chunrong Yu; Bret B Friday; Lin Yang; Peter Atadja; Dennis Wigle; Jann Sarkaria; Alex A Adjei
Journal:  Neuro Oncol       Date:  2008-04-29       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.